Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New Elite Feature:   Find Similar Charts in Seconds

Learn How
Market News Market Pulse Stocks News ETF News Crypto News

Purple Biotech Ltd.

Contributing Author

Recent Articles by Purple Biotech Ltd.

Sep-02
New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies PPBT +19.28% GlobeNewswire
Aug-07
Purple Biotech Reports Second Quarter 2026 Financial Results PPBT GlobeNewswire
Jun-11
Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window PPBT -47.97% GlobeNewswire
May-15
Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights PPBT +6.78% GlobeNewswire
Apr-27
Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240 PPBT GlobeNewswire
Apr-23
Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform PPBT -8.08% GlobeNewswire
Mar-25
Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform PPBT GlobeNewswire
Mar-17
Purple Biotech Regains Compliance with Nasdaq PPBT GlobeNewswire
Mar-13
Purple Biotech Announces CEO Transition PPBT +6.77% GlobeNewswire
Mar-13
Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results PPBT +6.77% GlobeNewswire
Feb-25
Purple Biotech Announces Plan to Implement ADS Ratio Change PPBT GlobeNewswire
Jan-07
Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240 PPBT GlobeNewswire
Dec-11
Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025 PPBT GlobeNewswire
Dec-04
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress PPBT +8.17% GlobeNewswire
Nov-14
Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update PPBT GlobeNewswire
Oct-29
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform PPBT +81.82% GlobeNewswire
Oct-20
Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification PPBT GlobeNewswire
Sep-10
Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance PPBT -5.28% GlobeNewswire
Sep-05
Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants PPBT -15.38% PPBT -9.24% GlobeNewswire
Sep-04
Purple Biotech Announces Pricing of Up To $18 Million Public Offering PPBT -45.07% GlobeNewswire
Sep-04
Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai PPBT -45.07% GlobeNewswire
Sep-03
Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2 PPBT GlobeNewswire
Aug-27
Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference PPBT GlobeNewswire
Aug-06
Purple Biotech Reports Second Quarter 2025 Financial Results PPBT GlobeNewswire
Jul-23
Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025 PPBT GlobeNewswire
Jun-23
Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress PPBT GlobeNewswire
Jun-17
Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer PPBT GlobeNewswire
Jun-04
Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform PPBT GlobeNewswire
May-21
Purple Biotech Reports First Quarter 2025 Financial Results PPBT GlobeNewswire
May-12
Purple Biotech Appoints Shai Lankry as Chief Financial Officer PPBT GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)